| Clinically significant pharmacokinetic interactions between dietary caffeine and medications JA Carrillo, J Benitez Clinical pharmacokinetics 39, 127-153, 2000 | 523 | 2000 |
| Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. L Bertilsson, JA Carrillo, ML Dahl, A Llerena, C Alm, U Bondesson, ... British journal of clinical pharmacology 38 (5), 471-473, 1994 | 391 | 1994 |
| Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1 E Aklillu, JA Carrillo, E Makonnen, K Hellman, M Pitarque, L Bertilsson, ... Molecular pharmacology 64 (3), 659-669, 2003 | 234 | 2003 |
| Role of the smoking-induced cytochrome P450 (CYP) 1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine JA Carrillo, AG Herráiz, SI Ramos, G Gervasini, S Vizcaíno, J Benítez Journal of clinical psychopharmacology 23 (2), 119-127, 2003 | 226 | 2003 |
| Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2‐receptor antagonists C Martínez, C Albet, JAG Agúndez, E Herrero, JA Carrillo, M Márquez, ... Clinical pharmacology & therapeutics 65 (4), 369-376, 1999 | 187 | 1999 |
| Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine JA Carrillo, M Christensen, SI Ramos, C Alm, ML Dahl, J Benítez, ... Therapeutic drug monitoring 22 (4), 409-417, 2000 | 165 | 2000 |
| Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity JA Carrillo, ML Dahl, JO Svensson, C Alm, I Rodríguez, L Bertilsson Clinical Pharmacology & Therapeutics 60 (2), 183-190, 1996 | 158 | 1996 |
| CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine JA CARRILLO, J BENITEZ British journal of clinical pharmacology 41 (6), 605-608, 1996 | 153 | 1996 |
| Low daily 10‐mg and 20‐mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19) M Christensen, G Tybring, K Mihara, N Yasui‐Furokori, JA Carrillo, ... Clinical Pharmacology & Therapeutics 71 (3), 141-152, 2002 | 121 | 2002 |
| Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients JA Carrillo, AG Herraiz, SI Ramos, J Benitez Journal of clinical psychopharmacology 18 (4), 311-316, 1998 | 119 | 1998 |
| Caffeine metabolism in a healthy Spanish population: N‐Acetylator phenotype and oxidation pathways JA Carrillo, J Benítez Clinical Pharmacology & Therapeutics 55 (3), 293-304, 1994 | 110 | 1994 |
| Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy G Gervasini, J Benítez, JA Carrillo European journal of clinical pharmacology 66, 755-774, 2010 | 105 | 2010 |
| Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors E Arlander, G Ekström, C Alm, JA Carrillo, M Bielenstein, Y Böttiger, ... Clinical Pharmacology & Therapeutics 64 (5), 484-491, 1998 | 95 | 1998 |
| Adenosine triphosphate‐binding cassette B1 (ABCB1)(multidrug resistance 1) G2677T/A gene polymorphism is associated with high risk of lung cancer G Gervasini, JA Carrillo, M Garcia, C San Jose, A Cabanillas, J Benitez Cancer 107 (12), 2850-2857, 2006 | 94 | 2006 |
| Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients JA Carrillo, SI Ramos, AG Herraiz, A Llerena, JAG Agundez, R Berecz, ... Journal of clinical psychopharmacology 19 (6), 494-499, 1999 | 94 | 1999 |
| Analysis of midazolam and metabolites in plasma by high-performance liquid chromatography: probe of CYP3A JA Carrillo, SI Ramos, JAG Agundez, C Martinez, J Benitez Therapeutic drug monitoring 20 (3), 319-324, 1998 | 84 | 1998 |
| Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: modulation by endogenous compounds G Gervasini, JA Carrillo, J Benitez Clinical pharmacokinetics 43, 693-706, 2004 | 79 | 2004 |
| Debrisoquine oxidation phenotype during neuroleptic monotherapy. E Spina, C Martines, AP Caputi, J Cobaleda, B Pinas, JA Carrillo, ... European journal of clinical pharmacology 41 (5), 467-470, 1991 | 76 | 1991 |
| Differences in CYP3A5* 3 genotype distribution and combinations with other polymorphisms between Spaniards and other Caucasian populations G Gervasini, S Vizcaino, C Gasiba, JA Carrillo, J Benitez Therapeutic drug monitoring 27 (6), 819-821, 2005 | 65 | 2005 |
| CYP1A1gene polymorphisms increase lung cancer risk in a high-incidence region of Spain: a case control study C San Jose, A Cabanillas, J Benitez, JA Carrillo, M Jimenez, G Gervasini BMC cancer 10, 1-7, 2010 | 52 | 2010 |
Julio BenitezUniversity of ExtremaduraΗ διεύθυνση ηλεκτρονικού ταχυδρομείου έχει επαληθευτεί στον τομέα unex.es
